Mouse xenograft studies have shown that the DNA-PK inhibitor AZD7648 can enhance the efficacy of olaparib, a PARP1/2 inhibitor, in FaDu ATM knockout (KO) tumour models, since the loss of ATM has been shown to sensitise cells to DNA-PK inhibitor treatment [26,27]. This evidence concerns the gene PARP1 and neoplasm.